An experimental study of preventing and treating acute radioactive enteritis with human umbilical cord mesenchymal stem cells

Wang, Rui; Yuan, Wei; Zhao, Qiang; Song, Peng; Yue, Ji; Lin, Shide; Zhao, Tengda

doi:10.1016/s1995-7645(13)60173-x

Cited by 8 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 13 In addition to placental and adipose tissue, bone marrow-derived MSCs have been used in treatment of radiation-induced intestinal damage in mice, inducing regeneration of intestinal mucosa through intestinal stem cell differentiation, reduction of apoptosis and inflammation, and increased secretion of growth factors and cytokines. 14 15 16 17 18 19 …”

Section: Discussionmentioning

confidence: 99%

“…First, previous studies reported intravenous or intraperitoneal systemic injection of stem cells following whole body irradiation. 14 15 16 17 18 19 However, most radiation treatment for cervical, prostate, or rectal cancers focus on the lower pelvis, as well as injured sites in the rectum. Therefore, the present study used a regional irradiation model.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Mesenchymal Stem Cells Treatment on Radiation-Induced Proctitis in Rats

Kim

Yoo

et al. 2023

Yonsei Med J

View full text Add to dashboard Cite

Purpose There are no effective treatment methods with which to control complications of radiation proctitis with fistula or recurrent bleeding following radiation treatment for prostate, cervical, or rectal cancer. Mesenchymal stem cells (MSCs) can induce immune modification, resulting in tissue repair and regeneration. Therefore, we used a rat model of radiation-induced proctitis and observed the effects of using human placenta-derived (PD) and adipose tissue-derived (AD) MSCs. Materials and Methods Female Sprague Dawley rats were irradiated at the pelvic area with 25 Gy. We injected 1×10 6 cells of human PD-MSCs, human AD-MSCs, human foreskin fibroblasts, and control media into the rectal submucosa following irradiation. We sacrificed rats for pathologic evaluation. Results Fibrosis on the rectum was reduced in both MSC groups, compared to the control group. Mucosal Ki-67 indices of both MSC injected groups were higher than those in the control group. Although caspase-3 positive cells in the mucosa gradually increased and decreased in the control group, those in both MSC injected groups increased rapidly and decreased thereafter. Conclusion We demonstrated the effects of regional MSC injection treatment for radiation-induced proctitis in rats. MSC injection reduced fibrosis and increased proliferation in rat mucosa. Human AD-MSCs and PD-MSCs had similar effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effects of Mesenchymal Stem Cells Treatment on Radiation-Induced Proctitis in Rats

Kim

Yoo

et al. 2023

Yonsei Med J

View full text Add to dashboard Cite

show abstract

“…Cell-based approaches to established inflammation management have recently emerged and present a paradigm shift from the traditional protein and pharmaceutical compound mode of mucositis therapy. Mesenchymal stem cell (MSC) therapy has been investigated in autologous transplant to pigs and rats with radiation-induced proctitis [60,61]; transplant of human umbilical cord MSCs to mice with radiation-induced intestinal mucositis [62], and guinea pigs with radiationinduced oral mucositis [63]; and adipose-derived MSCs have shown effectiveness for resolving radiation-induced colonic inflammation [64]. The utility of MSCs to prevent oral mucositis induced by fractionated radiotherapy has also shown promising results in mice; interestingly, the positive modulation was dependent on the timing of MSC transplantation [65].…”

Section: Sophisticated Targeting Of Inflammationmentioning

confidence: 99%

The pathogenesis of mucositis: updated perspectives and emerging targets

Bowen

Al‐Dasooqi²,

Bossi

et al. 2019

Support Care Cancer

121

View full text Add to dashboard Cite

Mucositis research and treatment are a rapidly evolving field providing constant new avenues of research and potential therapies. The MASCC/ISOO Mucositis Study Group regularly assesses available literature relating to pathogenesis, mechanisms, and novel therapeutic approaches and distils this to summary perspectives and recommendations. Reviewers assessed 164 articles published between January 2011 and June 2016 to identify progress made since the last review and highlight new targets for further investigation. Findings were organized into sections including established and emerging mediators of toxicity, potential insights from technological advances in mucositis research, and perspective. Research momentum is accelerating for mucositis pathogenesis, and with this has come utilization of new models and interventions that target specific mechanisms of injury. Technological advances have the potential to revolutionize the field of mucositis research, although focused effort is needed to move rationally targeted interventions to the clinical setting.

show abstract

“…Введение МСК человека мышам с индуцированной химиотерапией с недостаточностью яичников способствовало, по данным мазков из влагалища, изменению уровня эстрогенов, репопуляции растущих фолликулов, снижению артериального давления и увеличению массы тела плода при эклампсии, отмене дегенеративных процессов в децидуальных клетках. Эффективность МСК показана при воспалительных процессах в желудочно-кишечном тракте [94][95][96]. МСК усиливают пролиферативный и регенераторный потенциал энтероцитов, восстановление проницаемости слизистых оболочек, заживление перианальных свищей и снижают степень тяжести колита, повреждение нервов в стенке толстой кишки, инфильтрацию нейтрофилами, а также способны к трансдифференцировке в кишечные стволовые клетки.…”

Section: терапевтический потенциал мскunclassified

Mesenchymal stem cells: properties and clinical application

Лыков

2023

Sibirskij nauchnyj medicinskij zhurnal

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can diﬀerentiate into various cell types, including adipocytes, osteocytes, chondrocytes, etc. MSCs can be isolated from various human and animal tissues. MSCs are characterized by high proliferative capacity, diﬀerentiation in the connective-tissue direction, paracrine and trophic activity (they produce a wide range of biologically active molecules), are capable of migrating to the zone of organ and tissue damage, and exhibit immunosuppression. There are similarities and diﬀerences between human and mammalian MSCs in phenotype and functional activity. The therapeutic potential of MSCs has been shown on experimental models and in clinical trials, which allows us to consider the MSC-oriented cell technologies as an alternative to traditional methods of treatment. The article presents a review and analysis of the literature devoted to the study of MSCs properties, signaling pathways involved in the regulation of cell activity, the prospects for the use of MSCs in the treatment of inﬂammatory and degenerative diseases. During preparation of the review full-text, free access articles for the period from 2006 to 2022 were taken from eLibrary and National Center for Biotechnology Information (NCBI) databases.

show abstract

An experimental study of preventing and treating acute radioactive enteritis with human umbilical cord mesenchymal stem cells

Abstract: Human umbilical cord-derived mesenchymal stem cells have a definite therapeutic effect on acute radioactive enteritis in rats.

Cited by 8 publications

References 1 publication

Effects of Mesenchymal Stem Cells Treatment on Radiation-Induced Proctitis in Rats

Effects of Mesenchymal Stem Cells Treatment on Radiation-Induced Proctitis in Rats

The pathogenesis of mucositis: updated perspectives and emerging targets

Mesenchymal stem cells: properties and clinical application

Contact Info

Product

Resources

About